Loading
HLB Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest was filed 09 Jun 2026.
HLB: what insiders have been doing
HLB, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The last twelve months, up to 18 October 2026, brought 9 filings signed by 6 insiders.
Open-market activity splits into 4 purchases and 2 sales; 3 insiders sit on the buying side and 2 insiders on the selling side. The amount is not disclosed for 6 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 major shareholder.
The most recent open-market purchase was published on 9 June 2026, 131 days ago. Filings reach the DART (FSS) feed a median of 7 days after the trade. This delay matters because a trade only becomes useful information once it is public.
For context, the typical company on the same exchange (median of 2,648 companies) published 7 filings over the same period, against 9 filings here. Over the whole record (from 2021), the tally stands at 32 purchases and 2 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Insider Decl.
81
Thresholds
n/a
Buy Volume
€257M
32 ops. · all time
Sell Volume
€40M
2 ops. · all time
Who traded when
BuySale진양곤3 buys1 sale
BlackRockFundAdvisors2 buys
삼성자산운용1 buy1 sale
김현민1 buy
성복경1 buy
Since the insiders bought
- -14.1%Entry ₩48,300 · Close 16 Oct 2026 ₩41,500
- -18.0%Entry ₩50,600 · Close 16 Oct 2026 ₩41,500
- -9.2%Entry ₩45,700 · Close 16 Oct 2026 ₩41,500
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 20,497 of 24,161 companies
27.0
score / 100
Value26
Quality28
FCF yld-2.0%
Earn yld-4.0%
EV/EBITDA·
ROE-48%
Gross mgn33%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩41,700
Analyst consensus
Income statement
Revenue₩84.2B
Gross profit₩27.7B33% margin
EBITDA-₩222.8B-265% margin
Net income-₩220.5B-219.1% margin
Valuation
Beta0.51
Balance sheet & cash
Market cap₩5.5T
Total debt₩284.9B
Free Cash Flow-₩110.1B
Debt / Equity97%
Profitability & ownership
ROE-48.5%
ROA-7.0%
% insiders9.1%
% institutions15.1%
Last declaration on 16 July 2026
Declarations85 total
Other
Other
Other
Other
1,391,297 sharesKRXDART:20260609000183
Canonical exit: 7 Sept 2026 (T+90)
44,728 sharesKRXDART:20260303001765
Canonical exit: 25 May 2026 (T+90)
25 of 85 declarations
About HLB
HLB is a healthcare and pharmaceutical company listed on the XKRX market. It focuses on developing innovative treatments and therapeutic solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
